Xenetic Biosciences Inc
$ 2.08
-5.45%
26 Dec - close price
- Market Cap 4,765,400 USD
- Current Price $ 2.08
- High / Low $ 2.17 / 2.01
- Stock P/E N/A
- Book Value 2.56
- EPS -2.04
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.32 %
- ROE -0.57 %
- 52 Week High 13.93
- 52 Week Low 1.90
About
Xenetic Biosciences Inc. is a cutting-edge biopharmaceutical firm headquartered in Framingham, Massachusetts, dedicated to revolutionizing cancer treatment through innovative therapies. Leveraging its proprietary XCART platform, the company specializes in the development of personalized chimeric antigen receptor T (CAR T) cell therapies that specifically target unique tumor neoantigens, thereby offering customized treatment solutions for patients. With a robust pipeline and a commitment to addressing critical unmet needs in oncology, Xenetic is poised to emerge as a leader in the dynamic landscape of personalized medicine, driving both efficacy and patient outcomes.
Analyst Target Price
$40.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-12 | 2025-08-12 | 2025-05-07 | 2025-03-19 | 2024-11-07 | 2024-08-09 | 2024-05-09 | 2024-03-21 | 2023-11-09 | 2023-08-10 | 2023-05-11 | 2023-03-22 |
| Reported EPS | -0.33 | -0.45 | -0.59 | -0.68 | -0.28 | -0.83 | -0.78 | -0.77 | -0.69 | -0.69 | -0.6 | -0.1 |
| Estimated EPS | -0.84 | -0.79 | -0.72 | -0.2 | -0.14 | -0.83 | -0.79 | -0.87 | -1.12 | -1.13 | -1.1 | -0.09 |
| Surprise | 0.51 | 0.34 | 0.13 | -0.48 | -0.14 | 0 | 0.01 | 0.1 | 0.43 | 0.44 | 0.5 | -0.01 |
| Surprise Percentage | 60.7143% | 43.038% | 18.0556% | -240% | -100% | 0% | 1.2658% | 11.4943% | 38.3929% | 38.9381% | 45.4545% | -11.1111% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: XBIO
2025-12-23 15:10:15
Xenetic Biosciences has extended its collaboration with Scripps Research and Dr. Alexey Stepanov's lab for an additional four months, effective November 1, 2025. This extension aims to further advance the development of Xenetic's systemic DNase I candidate, XBIO-015, in combination with CAR T-cell therapies for treating hematologic and solid tumors. Preclinical studies have shown promising results, and the company is progressing towards Phase 1 clinical development.
2025-12-22 15:10:15
Xenetic Biosciences, Inc. has extended its collaboration with The Scripps Research Institute and Dr. Alexey Stepanov's lab for an additional four months. This extension is aimed at further advancing the company's research and development program, which evaluates the combination of systemic DNase I (XBIO-015) and CAR T-cell therapies for various cancers. Preclinical studies have shown promising results, with DNase I enhancing CAR-T cell efficacy by reducing tumor burden and mitigating the immunosuppressive tumor microenvironment.
2025-12-18 16:09:07
Xenetic Biosciences, Inc. (NASDAQ:XBIO) announced the adjournment of its 2025 Annual Meeting of Stockholders due to a lack of a required quorum. The meeting has been reconvened for January 8, 2026, at 10:00 a.m. Eastern Time, and stockholders who have not yet voted are urged to do so. The record date for voting remains October 15, 2025.
2025-12-16 17:08:25
Xenetic Biosciences, Inc. announced a 4-month extension of its R&D collaboration with Scripps Research and Dr. Alexey Stepanov to further develop its systemic DNase I candidate, XBIO-015. Preclinical studies have shown that combining XBIO-015 with CAR T-cell therapies significantly reduces tumor burden and enhances CAR-T cell efficacy by degrading neutrophil extracellular traps (NETs). The company aims to advance its DNase-based technology toward Phase 1 clinical development for treating pancreatic carcinoma and other solid tumors.
2025-12-15 17:09:33
Xenetic Biosciences, Inc. (NASDAQ:XBIO) has extended its research and development collaboration with Scripps Research and Dr. Alexey Stepanov's lab for an additional four months, effective November 1, 2025. This collaboration aims to further advance Xenetic's systemic DNase I candidate, XBIO-015, in combination with CAR T-cell therapies for various cancers. Preclinical studies have shown that co-administering DNase I with CAR-T cells significantly reduces tumor burden, decreases metastatic lesions, and extends survival by mitigating the immunosuppressive tumor microenvironment.
2025-12-14 15:09:55
Xenetic Biosciences, Inc. (NASDAQ: XBIO) announced the adjournment of its 2025 Annual Meeting of Stockholders due to a lack of quorum. The meeting will reconvene virtually on January 8, 2026, at 10:00 a.m. Eastern Time, and the company urges stockholders who have not yet voted to submit their proxies. The record date for voting remains October 15, 2025.
